Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection

Lehmann, Brian D.; Jovanović, Bojana; Chen, Xi; Estrada, Mónica V.; Johnson, Kimberly N.; Shyr, Yu; Moses, Harold L.; Sanders, Melinda E.; Pietenpol, Jennifer A.

doi:10.1371/journal.pone.0157368

articlePLoS ONEJun 16, 2016GOLD OA

Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection

BDBrian D. Lehmann BJBojana Jovanović XCXi Chen MVMónica V. Estrada KNKimberly N. Johnson

Vanderbilt University · Harvard University · +4 more institutions

PubMed

Indexed incrossrefdoajpubmed

Abstract

Triple-negative breast cancer (TNBC) is a heterogeneous disease that can be classified into distinct molecular subtypes by gene expression profiling. Considered a difficult-to-treat cancer, a fraction of TNBC patients benefit significantly from neoadjuvant chemotherapy and have far better overall survival. Outside of BRCA1/2 mutation status, biomarkers do not exist to identify patients most likely to respond to current chemotherapy; and, to date, no FDA-approved targeted therapies are available for TNBC patients. Previously, we developed an approach to identify six molecular subtypes TNBC (TNBCtype), with each subtype displaying unique ontologies and differential response to standard-of-care chemotherapy.…

Citation impact

1,399

total citations

FWCI: 36.39
Percentile: 100%
References: 37

Citations per year

Authors

9

Topics & keywords

Topics

Keywords

Triple-negative breast cancer
Breast cancer
Chemotherapy
Medicine
Oncology
Neoadjuvant therapy
Cancer
Internal medicine

UN Sustainable Development Goals

Good health and well-being

No related works found for this paper.